Ferriprox is a drug owned by Chiesi Usa Inc. It is protected by 8 US drug patents filed from 2019 to 2023. Out of these, 7 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 25, 2038. Details of Ferriprox's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10940116 | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(13 years from now) | Active |
| US11723874 | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(13 years from now) | Active |
| US11357731 | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(13 years from now) | Active |
| US10940115 | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(13 years from now) | Active |
| US10780055 | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(13 years from now) | Active |
| US11458103 | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(13 years from now) | Active |
| US8703156 | Liquid formulation for deferiprone with palatable taste |
Oct, 2029
(4 years from now) | Active |
| US7049328 | Use for deferiprone |
Jun, 2021
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ferriprox's patents.
Latest Legal Activities on Ferriprox's Patents
Given below is the list of recent legal activities going on the following patents of Ferriprox.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical | 15 Aug, 2023 | US11723874 |
| Recordation of Patent Grant Mailed Critical | 15 Aug, 2023 | US11723874 |
| Electronic Review Critical | 15 Aug, 2023 | US11723874 |
| Email Notification Critical | 15 Aug, 2023 | US11723874 |
| Patent eGrant Notification | 15 Aug, 2023 | US11723874 |
| Recordation of Patent eGrant | 15 Aug, 2023 | US11723874 |
| Mail Patent eGrant Notification | 15 Aug, 2023 | US11723874 |
| Electronic Review Critical | 27 Jul, 2023 | US11723874 |
| Email Notification Critical | 27 Jul, 2023 | US11723874 |
| Issue Notification Mailed Critical | 26 Jul, 2023 | US11723874 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Ferriprox and ongoing litigations to help you estimate the early arrival of Ferriprox generic.
Ferriprox's Litigations
Ferriprox been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 16, 2017, against patent number US7049328. The petitioner Taro, challenged the validity of this patent, with ApoPharma Inc. as the respondent. Click below to track the latest information on how companies are challenging Ferriprox's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7049328 | May, 2017 |
Terminated-Settled
(07 Aug, 2018) | ApoPharma Inc. | Taro |
FDA has granted some exclusivities to Ferriprox. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Ferriprox, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Ferriprox.
Exclusivity Information
Ferriprox holds 9 exclusivities out of which 4 have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Ferriprox's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 14, 2016 |
| Orphan Drug Exclusivity(ODE) | Oct 14, 2018 |
| Orphan Drug Exclusivity(ODE-16) | Oct 14, 2018 |
| New Indication(I-859) | Apr 30, 2024 |
| Orphan Drug Exclusivity(ODE-417) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-418) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-419) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-420) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-421) | Apr 30, 2028 |
US patents provide insights into the exclusivity only within the United States, but Ferriprox is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ferriprox's family patents as well as insights into ongoing legal events on those patents.
Ferriprox's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ferriprox's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 25, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ferriprox Generic API suppliers:
Deferiprone is the generic name for the brand Ferriprox. 2 different companies have already filed for the generic of Ferriprox, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ferriprox's generic
How can I launch a generic of Ferriprox before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Ferriprox's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Ferriprox's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Ferriprox -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 500 mg | 29 Jan, 2016 | 1 | 08 Feb, 2019 | 28 Jun, 2021 | Eligible |
About Ferriprox
Ferriprox is a drug owned by Chiesi Usa Inc. It is used for managing transfusional iron overload. Ferriprox uses Deferiprone as an active ingredient. Ferriprox was launched by Chiesi in 2020.
Approval Date:
Ferriprox was approved by FDA for market use on 19 May, 2020.
Active Ingredient:
Ferriprox uses Deferiprone as the active ingredient. Check out other Drugs and Companies using Deferiprone ingredient
Treatment:
Ferriprox is used for managing transfusional iron overload.
Dosage:
Ferriprox is available in the following dosage forms - solution form for oral use, tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1GM | TABLET | Prescription | ORAL |
| 100MG/ML | SOLUTION | Prescription | ORAL |
| 80MG/ML | SOLUTION | Discontinued | ORAL |
| 500MG | TABLET | Prescription | ORAL |